文献速递腹部MR

在大鼠肝转移瘤模型中评估无蛋白结合的高弛豫率大环磁共振对比剂钆匹醇与P846:超高场强下改善增强的潜在方案

Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
PubMed 文献 · Invest Radiol · 2019-01-01

本研究在9.4 T动物扫描仪上比较了实验性对比剂P846、钆匹醇与临床常用低分子对比剂钆喷酸葡胺、钆特酸葡胺的弛豫率和在体增强效果。体外显示钆匹醇在9.4 T下r1最高,P846从1.5 T到9.4 T r1明显下降;在体大鼠肝转移瘤模型中,P846和钆匹醇的SNR、CNR和病灶增强均显著高于对照对比剂,CNR提高约2.5至3倍。

要点

  • 在9.4 T下,钆匹醇r1为8.7 mM s,高于钆特酸葡胺3.1 mM s和钆喷酸葡胺3.4 mM s。
  • P846从1.5 T到9.4 T r1由32 mM s降至6.4 mM s,下降明显。
  • 等钆剂量下钆匹醇和P846使肝转移瘤CNR较对照对比剂提高约2.5至3倍。

核心结论

  • P846和钆匹醇在9.4 T下增强效果优于钆喷酸葡胺和钆特酸葡胺,但P846从1.5 T到9.4 T r1下降明显;作者认为适度增加分子大小和水合数的化合物(如钆匹醇)似乎是开发高效钆对比剂的有前景途径,但这一切仍需临床研究证实。

研究设计与样本

  • 实验性体外弛豫率测定联合在体动物研究,使用9.4 T动物扫描仪(Bruker,德国),在37°C人血浆中以IR-RARE序列测量所有对比剂弛豫率;在体部分将P846与钆喷酸葡胺、钆匹醇与钆特酸葡胺在大鼠肝结直肠癌转移模型中个体内比较(每组n=10),采集T1加权FLASH序列,注射前及注射后20分钟内连续10个时间点。

关键影像表现/征象

  • 在体大鼠肝转移瘤模型中,P846组肝脏SNR为27.2±1.5、肿瘤SNR为40.1±1.9、CNR为12.9±0.9、病灶增强为14.9±1.9,均显著高于钆喷酸葡胺组(肝脏SNR 18.1±1.2、肿瘤SNR 22.6±1.9、CNR 4.6±1.0、病灶增强7.2±1.9),P<0.001。
  • 钆匹醇组肝脏SNR为12.6±1.3、肿瘤SNR为20.9±2.9、CNR为8.3±1.7、病灶增强为13.0±2.9,均显著高于钆特酸葡胺组(肝脏SNR 8.8±0.5、肿瘤SNR 11.3±1.2、CNR 2.5±0.7、病灶增强4.4±1.2),P<0.001。
  • 等钆剂量下,钆匹醇和P846在9.4 T使肝转移瘤CNR较钆特酸葡胺和钆喷酸葡胺提高约2.5至3倍。

诊断标准与关键数值

  • 9.4 T下钆喷酸葡胺r1为3.4 mM s,低于1.5 T下的4.1 mM s;钆特酸葡胺9.4 T下r1为3.1 mM s,低于1.5 T下的3.6 mM s。
  • P846在9.4 T下r1为6.4 mM s,明显低于1.5 T下的32 mM s。
  • 钆匹醇在9.4 T下r1为8.7 mM s,为本研究中最高,且较低场强1.5 T下的12.7 mM s下降幅度较小。

临床应用与阅片要点

  • 作者认为,构建适度增加分子大小和水合数的化合物(如钆匹醇)似乎是开发高效钆对比剂的有前景途径。
  • 作者指出钆匹醇的优势包括:不受外部磁场强度影响的强增强、药代动力学与临床批准的细胞外钆对比剂相当,以及有可能通过改善病灶显示提高诊断磁共振成像的敏感性,或在显著降低钆剂量的同时保持相当的诊断准确性。
  • 作者指出上述优势均需在临床研究中证实。

局限性

  • 原文在结论中写明,钆匹醇的上述潜在优势均需在临床研究中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to evaluate in vitro and in vivo the enhancement properties of experimental gadolinium (Gd)-based contrast agents (GBCAs) with different molecular weights and hydration numbers (P846 and gadopiclenol) compared with clinically approved low-molecular, extracellular agents (gadopentetate and gadoterate) at 9.4 T and to discuss influencing factors on r1 relaxivities.

METHODS AND MATERIALS: All experiments were performed with a 9.4 T animal scanner (Bruker, Germany). We performed relaxometry measurements for all contrast agents in human plasma at 37°C using an IR-RARE sequence. In addition, we compared P846 with gadopentetate and gadopiclenol with gadoterate intraindividually in rats with hepatic colorectal cancer metastases (n = 10 each) acquiring T1-weighted FLASH sequences before and at 10 consecutive time points during 20 minutes. After intravenous contrast agent application, signal-to-noise ratios (SNRs), contrast-to-noise ratios (CNRs), and lesion enhancement (LE) for liver parenchyma and tumors were calculated based on region of interest measurements.

RESULTS: Longitudinal relaxivities (r1) of the low-molecular agents were lower as compared with the experimental compounds. However, r1 of gadopentetate and gadoterate demonstrated only a moderate decrease of r1 at 9.4 T as compared with known data at lower field strengths (gadopentetate: r1 [at 9.4 T], 3.4 mM s/r1 [at 1.5 T], 4.1 mM s/gadoterate: r1 [at 9.4 T], 3.1 mM s/r1 [at 1.5 T], 3.6 mM s). In contrast, r1 of P846 showed a marked reduction at 9.4 T compared with 1.5 T (P846: r1 [at 9.4 T], 6.4 mM s/r1 [at 1.5 T], 32 mM s). Gadopiclenol provided the highest r1 in this study at 9.4 T and the drop of r1 as compared with lower field strength is less apparent (gadopiclenol: r1 [at 9.4 T], 8.7 mM s/r1 [at 1.5 T], 12.7 mM s).In vivo, P846 and gadopiclenol showed significantly higher SNR, CNR, and LE as compared with the low-molecular control agents (mean ± SD; SNRliver [gadopentetate, 18.1 ± 1.2; P846, 27.2 ± 1.5; P < 0.001]; SNRtumor [gadopentetate, 22.6 ± 1.9; P846, 40.1 ± 1.9; P < 0.001]; CNR [gadopentetate, 4.6 ± 1.0; P846, 12.9 ± 0.9; P < 0.001]; LE [gadopentetate, 7.2 ± 1.9; P846, 14.9 ± 1.9; P < 0.001]/SNRliver [gadoterate, 8.8 ± 0.5; gadopiclenol, 12.6 ± 1.3; P < 0.001]; SNRtumor [gadoterate, 11.3 ± 1.2; gadopiclenol, 20.9 ± 2.9; P < 0.001]; CNR [gadoterate, 2.5 ± 0.7; gadopiclenol, 8.3 ± 1.7; P < 0.001]; LE [gadoterate, 4.4 ± 1.2; gadopiclenol, 13.0 ± 2.9; P < 0.001]). Thus, for equal Gd doses, gadopiclenol and P846 increase the CNR of liver metastases by a factor of 2.5 to 3 at 9.4 T compared with gadoterate and gadopentetate.

CONCLUSIONS: P846 and gadopiclenol provide superior enhancement at 9.4 T as compared with gadopentetate and gadoterate. However, the macromolecular agent P846 shows a marked decrease of r1 from 1.5 T to 9.4 T. This effect is less apparent for the low-molecular agents gadopiclenol, gadopentetate, and gadoterate. Yet, based on the higher hydration number, r1 of P846 and gadopiclenol are markedly higher as compared with the reference contrast agents. Thus, building compounds with moderately increased molecular size and hydration number, as implemented in gadopiclenol, seems to be a promising way to develop highly effective GBCAs.Advantages for gadopiclenol include a strong enhancement regardless of the external magnetic field strength, pharmacokinetics comparable to those of clinically approved extracellular GBCAs, and the potential to either improve sensitivity in diagnostic magnetic resonance imaging by improving lesion conspicuity or to perform studies with significantly reduced Gd-dose while at the same time providing comparable diagnostic accuracy. However, all this needs to be proven in clinical studies.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Fries P, Massmann A, Robert P, et al. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength. Invest Radiol. 2019. PMID: 31033675. doi:10.1097/RLI.0000000000000572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。